{"id":72784,"date":"2016-05-02T12:00:38","date_gmt":"2016-05-02T11:00:38","guid":{"rendered":"https:\/\/www.transcend.org\/tms\/?p=72784"},"modified":"2016-04-29T15:27:50","modified_gmt":"2016-04-29T14:27:50","slug":"valeant-ceo-to-tell-senate-hes-really-really-sorry-for-raising-the-price-of-life-saving-heart-drugs-700-percent","status":"publish","type":"post","link":"https:\/\/www.transcend.org\/tms\/2016\/05\/valeant-ceo-to-tell-senate-hes-really-really-sorry-for-raising-the-price-of-life-saving-heart-drugs-700-percent\/","title":{"rendered":"Valeant CEO to Tell Senate He\u2019s Really, Really Sorry for Raising the Price of Life-Saving Heart Drugs 700 Percent"},"content":{"rendered":"<div id=\"attachment_72785\" style=\"width: 310px\" class=\"wp-caption alignright\"><a href=\"https:\/\/www.transcend.org\/tms\/wp-content\/uploads\/2016\/04\/23-michael-pearson.w529.h529-valeant-big-pharma.jpg\" ><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-72785\" class=\"wp-image-72785\" src=\"https:\/\/www.transcend.org\/tms\/wp-content\/uploads\/2016\/04\/23-michael-pearson.w529.h529-valeant-big-pharma.jpg\" alt=\"Pearson &quot;regrets&quot; price gouging. Photo: Kevin Van Paassen\/Bloomberg via Getty Images \" width=\"300\" height=\"300\" srcset=\"https:\/\/www.transcend.org\/tms\/wp-content\/uploads\/2016\/04\/23-michael-pearson.w529.h529-valeant-big-pharma.jpg 529w, https:\/\/www.transcend.org\/tms\/wp-content\/uploads\/2016\/04\/23-michael-pearson.w529.h529-valeant-big-pharma-150x150.jpg 150w, https:\/\/www.transcend.org\/tms\/wp-content\/uploads\/2016\/04\/23-michael-pearson.w529.h529-valeant-big-pharma-300x300.jpg 300w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><p id=\"caption-attachment-72785\" class=\"wp-caption-text\">Pearson &#8220;regrets&#8221; price gouging. Photo: Kevin Van Paassen\/Bloomberg via Getty Images<\/p><\/div>\n<p><em>27 Apr 2016 &#8211; <\/em>J. Michael Pearson, ex-CEO of Valeant\u00a0Pharmaceuticals, would like the Senate to know he has made some mistakes. As head of Valeant, Pearson made <a target=\"_blank\" href=\"http:\/\/nymag.com\/daily\/intelligencer\/2016\/03\/why-the-fall-of-valeants-ceo-is-good-for-you.html\" >enormous profits<\/a> through a combination of corporate inversion, swindling investors, and jacking up the prices of decades-old drugs in such a way that forced insurance companies to foot the bill.<\/p>\n<p>Among other things, the company increased the price of Isuprel \u2014 a blood-pressure medication \u2014 by 720 percent and the price of Nitropress from $214 to $880. But in\u00a0prepared testimony before the Senate Special Committee on Aging, Pearson said he regrets his actions, Reuters <a target=\"_blank\" href=\"http:\/\/nymag.com\/daily\/intelligencer\/2016\/04\/creator.html\" >reports<\/a>.<\/p>\n<p>&#8220;The company was too aggressive \u2014 and I, as its leader, was too aggressive \u2014 in pursuing price increases on certain drugs,&#8221; Pearson said. &#8220;In\u00a0hindsight I regret pursuing transactions where a central premise was a planned increase in the prices of the medicines.&#8221;<\/p>\n<p>Pearson went on to say that he regrets the acquisition of both Isuprel and Nitropress\u00a0from Marathon Pharmaceuticals, a separate company, in 2015:\u00a0&#8220;We should have abandoned the transaction with Marathon when it became clear that the expected arrival of generic competition made the economics of the deal dependent on significant price increases,&#8221; he said.<\/p>\n<p>His testimony comes as Valeant is facing multiple investigations into its drug pricing and accounting practices by U.S. prosecutors. The company is also about $30 billion in debt, its stock is down 90 percent, and its earnings releases have been delayed as it struggles to factor in just how much money it lost in 2016.<\/p>\n<p>Pearson recently stepped down as CEO to make way for Joseph Papa, who Pearson assured the Senate will &#8220;no longer be seeking to acquire mispriced drugs,&#8221; which seems like a step forward.<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/nymag.com\/daily\/intelligencer\/2016\/04\/valeant-ceo-tells-senate-he-regrets-price-gouge.html\" >Go to Original \u2013 nymag.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>As head of Valeant, Pearson made enormous profits through a combination of corporate inversion, swindling investors, and jacking up the prices of decades-old drugs in such a way that forced insurance companies to foot the bill.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-72784","post","type-post","status-publish","format-standard","hentry","category-capitalism"],"_links":{"self":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/posts\/72784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/comments?post=72784"}],"version-history":[{"count":0,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/posts\/72784\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/media?parent=72784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/categories?post=72784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/tags?post=72784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}